340B Drug Access Bill

Summary#

SB 1486 would create a new state law called the 340B Contract Pharmacy Protection Act. It would bar certain actions that interfere with access to 340B drugs, set a Medicaid claims method, and require grants for sexually transmitted disease clinics. Its stated goal is to protect access to these drugs and support clinic testing and treatment; it is an introduced bill, not law.

  • Manufacturers and their agents or affiliates, distributors, and third-party logistics providers could not interfere with delivery of 340B drugs to locations authorized by covered entities, unless federal law bars delivery.
  • Those same parties could not require covered entities to submit claims or use data as a condition of acquiring or receiving the drugs, unless federal law requires it.
  • The Department of Human Services (DHS) and other named Medicaid drug-benefit administrators must use only a claims-level method with a nationally recognized billing modifier to identify 340B drugs, remove those claims from specified encounter data, and exclude them from Medicaid drug rebate requests.
  • DHS must provide each sexually transmitted disease clinic a grant of at least $500 from specified federal funds, within 90 days of the relevant effective date. New or renewed awards to clinics must also provide at least $500.
  • The Office of Attorney General would enforce the drug-access rules. A violation could bring a $50,000 fine per violation—with each package counted separately—and, if not fixed within 30 days of written notice, suspension of the ability to do business in Pennsylvania.

What it means for you#

  • Covered entities and contract pharmacies: The bill would protect access to 340B drugs at locations the covered entity authorizes. Covered entities and contract pharmacies could ask Commonwealth Court for an injunction (a court order to stop or require an action). Federal law could still prohibit delivery.
  • Manufacturers, distributors and logistics providers: They would have to follow the access and data rules. The bill does not set out an application or review process for deciding whether conduct violates them.
  • DHS and Medicaid drug-benefit administrators: They must use the specified claims method. The bill defines “covered insurer” to exclude Medicaid fee-for-service, but separately names DHS; how the method applies across Medicaid arrangements is unclear.
  • Sexually transmitted disease clinics: Each clinic must receive at least $500 from the specified federal funding for testing and treatment. The bill does not say how much any clinic would receive above that minimum.
  • Other residents: The bill does not directly change individual drug eligibility, create a general patient benefit, or impose a tax.

Money#

No cost information is in the available material.

  • DHS would have to use federal funding for grants of at least $500 per clinic and include at least $500 in new or renewed clinic awards. The bill gives no total funding estimate or number of clinics.
  • The bill requires DHS to use staff and other resources to carry out its duties, but gives no staffing or administrative cost estimate.
  • The bill sets fines, but does not say where fine revenue would go.

What is unclear#

  • “Sexually transmitted disease clinic” is not defined, and the bill does not explain how DHS would identify eligible clinics or distribute grants.
  • The bill does not name the billing modifier or explain how the required claims method would work in practice.
  • The text gives no process for investigating alleged violations, challenging a fine, or reviewing a business suspension.
  • The fine provision lists some parties differently from the access prohibition, which also names distributors generally. The suspension provision refers to notice under a different subsection than the one that sets out written notice; how these provisions fit together is unclear.
  • The existing Unfair Trade Practices and Consumer Protection Law was not supplied, so its current enforcement process and how it would interact with this bill cannot be verified. No publicly available information is supplied here about the bill’s fiscal effects.

Case for#

  • The bill appears intended to prevent drug suppliers from blocking covered entities’ access to 340B drugs at authorized locations.
  • Limiting demands for claims or use data as a condition of access could prevent those demands from being used to restrict delivery, while retaining an exception for federal requirements.
  • A single claims-level method could make Medicaid identification of 340B drugs more consistent with the encounter-data and rebate rules named in the bill.
  • A minimum grant would require some federal funding to reach every qualifying clinic for testing and treatment.

Case against#

  • The bill sets large potential fines: each package tied to a violation counts separately, so one course of conduct could lead to many counted violations.
  • “Otherwise interfere” is broad, and the bill does not spell out how the Attorney General would decide what conduct crosses the line.
  • The claims method is required, but the bill does not name the modifier or explain how it would operate across different Medicaid arrangements.
  • A $500 minimum may provide little support to a clinic, while the bill gives no total grant budget or estimate of how many clinics must receive grants.